Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom

Das R, Cope S, Ouwens M, Turner P, Howlett M

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.clinthera.2013.01.011

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Agents, Hormonal /economics /therapeutic use; Aromatase Inhibitors /economics /therapeutic use; Breast Neoplasms /drug therapy; Drug Costs; Estradiol /analogs & derivatives /economics /therapeutic use; Great Britain; Humans; Survival Analysis

AccessionNumber
22013013890

Date bibliographic record published
01/05/2013